REG - Tissue Regenix Group - Statement re. Suspension

Tissue RegenixAnnouncement

22/10/2025 15:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251022:nRSV4424Ea&default-theme=true

RNS Number : 4424E  Tissue Regenix Group PLC  22 October 2025

 Tissue Regenix Group plc

('Tissue Regenix', the 'Company')

 

Statement re. Suspension

 

Tissue Regenix plc (AIM: TRX), the regenerative medical devices company,
announces that it has requested the temporary suspension of trading on AIM of
the Company's ordinary shares, which has taken place with immediate effect.

 

The temporary suspension will allow the new Senior Leadership Team to further
consider the previously announced restatement of revenue numbers for the
financial year ended 31 December 2024 ("FY24"), the impact this has on H125
adjusted EBITDA, and the cash-position and ongoing expected performance of the
business. Until this further review takes place the Company is not in a
position to clarify its financial position.

 

Strict financial controls are being implemented, and a comprehensive review of
the Group's cost structure is already underway, targeting a $2m+ cost
reduction.

 

The Board remain committed to ensuring the recovery of the business and
delivering sustainable, long-term earnings growth for shareholders. Further
announcements will be made in due course.

 

 

 

For more information:

 

 Tissue Regenix Group plc                                              www.tissueregenix.com (http://www.tissueregenix.com)
 Jay LeCoque, Executive Chairman                                       via Walbrook PR

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)
 Geoff Nash/Giles Balleny/Edward Whiley                                Tel: +44 (0) 20 7466 5000
 Nigel Birks - Life Science Specialist Sales
 Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)  Tel: +44 (0)20 7933 8780 or TissueRegenix@walbrookpr.com
 Alice Woodings / Paul McManus      Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
'MAR' EU no. 596/2014. Upon the publication of this announcement via the
Regulatory Information Service 'RIS', this inside information is now
considered to be in the public domain.

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle injuries and
wound care.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  SRSFLFFSIELFFIE



            Copyright 2019 Regulatory News Service, all rights reserved